Animal models for assessing countermeasures to bioterrorism agents

Animal Models for Assessing Countermeasures to Bioterrorism Agents

Volumn , Issue , 2012, Pages 1-137

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85024098966     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.17226/13233     Document Type: Book

References (251)

1. Achtman M, Zurth K, Morelli G, Torrea G, Guiyoule A, Carniel E. 1999. Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis. Proc Natl Acad Sci USA 96(24):14043-14048.
2. Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, Stavale E, Wang P, Chang S, Tang Q, Porter K, Goldblatt M, Bavari S. 2009. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res 83(3):245-251.
3. Bovania A, Diaz LS, Santos D, Cassella J, Fesseha Z, Bamba D, Sui B, Li W-B, Duan R, Chen L-M, Donis RO, Goldblatt M, Kinch MS. 2010. Antibody targeting of TSG101 on influenza-infected cells. Virus Adaptation and Treatment 2:147-157.
4. Chen H, Liu X, Li Z, Zhan P, De Clercq P. 2010. TSG101: A novel anti-HIV-1 drug target. Curr Med Chem 17(8):750-758.
5. DoD [U.S. Department of Defense]. 2006. Quadrennial Defense Review Report. Available online (http://www.defense.gov/qdr/report/Report20060203.pdf), accessed May 2011.
6. Eppinger M, Worsham PL, Nikolich MP, Riley DR, Sebastian Y, Mou S, Achtman M, Lindler LE, Ravel J. 2010. Genome sequence of the deep-rooted Yersinia pestis strain Angola reveals new insights into the evolution and pangenome of the plague bacterium. J Bacteriol 192(6):1685-1699.
7. FDA [Food and Drug Administration]. 2002. New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible. Fed Regist 67(105):37988-37998.
8. Lederberg J. 2000. Infectious history. Science 288:287-293. Lindler L, Choffnes E, Korch G. 2005. Definition and overview of emerging threats. In: Lindler L, Lebeda F, Korch G, eds. Biological Weapons Defense: Infectious Disease and Couterbioterrorism. New Jersey: Humana Press. p 351-360.
9. Lindler L, Choffnes E, Korch G. 2005. Definition and overview of emerging threats. In: Lindler L, Lebeda F, Korch G, eds. Biological Weapons Defense: Infectious Disease and Couterbioterrorism. New Jersey: Humana Press. p 351-360
10. Martin-Serrano J, Zang T, Bieniasz PD. 2001. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med 7(12):1313-1319.
11. Petro JB, Plasse TR, McNulty JA. 2003. Biotechnology: Impact on biological warfare and biodefense. Biosecur Bioterror 1(3):161-168.
12. Rambaut A, Posada D, Crandall KA, Holmes EC. 2004. The causes and consequences of HIV evolution. Nat Rev Genet 5(1):52-61.
13. Warren TK, Warfield KL, Wells J, Enterlein S, Smith M, Ruthel G, Yunus AS, Kinch MS, Goldblatt M, Aman MJ, Bavari S. 2010. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob Agents Chemother. 54(5):2152-2159.
14. Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S. 2010. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 16(9):991-994.
15. Alves DA, Glynn AR, Steele KE, Lackemeyer MG, Garza NL, Buck JG, Mech C, Reed DS. 2010. Aerosol exposure to the Angola strain of Marburg virus causes lethal viral hemorrhagic fever in cynomolgus macaques. Vet Pathol 47(5):831-851.
16. Anderson J, Tucker K. 2006. Development and validation of animal models. In: Swearengen JR, ed. Biodefense: Research Methodology and Animal Models. Boca Raton: CRC Press. p 41-60.
17. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga I, Lansoud-Soukate J, Mavoungou E. 2002. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 128(1):163-168.
18. Baize S, Leroy EM., Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debré P, Fisher-Hoch SP, McCormick JB, Georges AJ. 1999. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5(4):423-426.
19. Barrette RW, Metwally SA, Rowland JM, Xu L, Zaki SR, Nichol ST, Rollin PE, Towner JS, Shieh WJ, Batten B, Sealy TK, Carrillo C, Moran KE, Bracht AJ, Mayr GA, Sirios-Cruz M, Catbagan DP, Lautner EA, Ksiazek TG, White WR, McIntosh MT. 2009. Discovery of swine as a host for the Reston ebolavirus. Science 325(5937):204-206.
20. Baskerville A, Bowen ET, Platt GS, McArdell LB, Simpson DI. 1978. The pathology of experimental Ebola virus infection in monkeys. J Pathol 125(3):131-138.
21. Baskerville A, Fisher-Hoch SP, Neild GH, Dowsett AB. 1985. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J Pathol 147(3):199-209.
22. Bausch DG, Nichol ST, Muyembe-Tamfum JJ, Borchert M, Rollin PE, Sleurs H, Campbell P, Tshioko FK, Roth C, Colebunders R, Pirard P, Mardel S, Olinda LA, Zeller H, Tshomba A, Kulidri A, Libande ML, Mulangu S, Formenty P, Grein T, Leirs H, Braack L, Ksiazek T, Zaki S, Bowen MD. Smit SB, Leman PA, Burt FJ, Kemp A, Swanepoel R; International Scientific and Technical Committee for Marburg Hemorrhagic Fever Control in the Democratic Republic of the Congo. 2006. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med 355(9):909-919.
23. Beall FA, Dalldorf FG. 1966. The pathogenesis of the lethal effect of anthrax toxin in the rat. J Infect Dis 116(3):377-389.
24. Bechtelsheimer H, Korb G, Gedigk P. 1970. The "Marburg-virus" hepatitis. Studies in man and guinea pigs [in German]. Arch A Pathol Pathol Anat 351(4):273-290.
25. Bowen ET, Platt GS, Simpson DI, McArdell LB, Raymond RT. 1978. Ebola haemorrhagic fever: Experimental infection of monkeys. Trans R Soc Trop Med Hyg 72(2):188-191.
26. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. 1962. Field evaluation of a human anthrax vaccine. Am J Public Health 52(4):632-645.
27. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 178(3):651-661.
28. Bwaka MA, Bonnet MJ, Calain P, Colebunders R, de Roo A, Guimard Y, Katwiki KR, Kibadi K, Kipasa MA, Kuvula KJ, Mapanda BB, Massamba M, Mupapa KD, Muyembe-Tamfum JJ, Ndaberey E, Peters CJ, Rollin PE, van den Enden E. 1999. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: Clinical observations in 103 patients. J Infect Dis 179(suppl 1): S1-S7.
29. Carrion R Jr, Ro Y, Hoosien K, Ticer A, Brasky K, de la Garza M, Mansfield K, Patterson JL. 2011. A small nonhuman primate model for filovirus-induced disease. Virology 420(2):117-124.
30. Chand HS, Drysdale M, Lovchik J, Koehler TM, Lipscomb MF, Lyons CR. 2009. Discriminating virulence mechanisms among Bacillus anthracis strains by using a murine subcutaneous infection model. Infect Immun 77(1):429-435.
31. Conlan JW, Chen W, Shen H, Webb A, KuoLee R. 2003. Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: Bacteriologic and histopathologic studies. Microb Pathog 34(5):239-248.
32. Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, Jaax NK, Jahrling PB. 1999. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 179(suppl. 1):S203-S217.
33. Coriell LL, Downs CM, Clapp MP. 1947. Studies on tularemia; immunization of mice. J Immunol 56(3):245-253.
34. Craig AD. 2009. A rat is not a monkey is not a human: Comment on Mogil (Nature Rev Neurosci 10:283-294 [2009]). Nature Rev Neurosci 10(6):466.
35. Craig AD. 2009. A rat is not a monkey is not a human: Comment on Mogil Nature Rev Neurosci 10(6):466.
36. Crawford LM. 2004. Presentation for Banc of America Securities, Healthcare Institutional Investor Conference, July 7, 2004. Available online (http://www.fda.gov/newsEvents/Speeches/ucm053444.htm), accessed August 2011.
37. Dadaeva AA, Sizikova LP, Subbotina EL, Chepurnov AA. 2006. Hematological and immunological parameters during Ebola virus passages in guinea pigs [in Russian]. Vopr Virusol 51(4):32-37.
38. Dietrich M, Schumacher HH, Peters D, Knobloch J. 1978. Human pathology of Ebola (Maridi) virus infection in the Sudan. In: Pattyn SR, ed. Ebola Virus Haemorrhagic Fever: Proceedings of an International Colloquium on Ebola Virus Infection and Other Haemorrhagic Fevers, December 6-8, 1977, Antwerp, Belgium. Amsterdam: Elsevier/North-Holland Biomedical Press. p 37-41.
39. DiMasi JA. 2001. Risks in new drug development: Approved success rates for investigational drugs. Clin Pharmacol Ther 69(5):297-307.
40. DiMasi JA, Feldman L, Seckler A, Wilson A. 2010. Trends in risks associated with new drug development: Success rates for investigational drugs. Clin Pharmacol Ther 87(3):272-277.
41. DiMasi JA, Grabowski HG. 2007. The cost of biopharmaceutical R&D: Is biotech different? Manage Decis Econ 28(4-5):469-479.
42. Downs CM, Buchele L, Edgar EP. 1949. Studies on pathogenesis and immunity in tularemia; the pathogenesis of tularemia in the white rat. J Immunol 63(2):117-133.
43. Ellis DS, Simpson IH, Francis DP, Knobloch J, Bowen ET, Lolik P, Deng IM. 1978. Ultrastructure of Ebola virus particles in human liver. J Clin Pathol 31(3):201-208.
44. Falzarano D, Geisbert TW, Feldmann H. 2011. Progress in filovirus vaccine developement: Evaluating the potential for clinical use. Expert Rev Vaccines 10(1):63-77.
45. FDA [Food and Drug Administration]. 1973. Anthrax Vaccine, Adsorbed. Fed Regist 38 (223):32067-32068 [Established in Title 21 of the Code of Federal Regulations Sections 620.20 -620.25 for Anthrax Vaccine, Adsorbed (AVA)].
46. FDA. 2002. New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible. Fed Regist 67(105):37988-37998. Available online (http://www.fda.gov/OHRMS/DOCKETS/98fr/053102a.htm), accessed March 2011.
47. Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, Friedlander AM. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19(23-24):3241-3247. Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A. 1999. Human infection due to Ebola virus, subtype Côte d'Ivoire: Clinical and biologic presentation. J Infect Dis 179 (suppl 1):S48-S53.
48. Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A. 1999. Human infection due to Ebola virus, subtype Côte d'Ivoire: Clinical and biologic presentation. J Infect Dis 179 (suppl 1):S48-S53.
49. Gear JS, Cassel GA, Gear AJ, Trappler B, Clausen L, Meyers AM, Kew MC, Bothwell TH, Sher R, Miller GB, Schneider J, Koornhof HJ, Gomperts ED, Isaäcson M, Gear JH. 1975. Outbreak of Marburg virus disease in Johannesburg. Br Med J 4(5995):489-493.
50. Gedigk P, Bechtelsheimer H, Korb G. 1968. Pathological anatomy of the "Marburg virus"disease (the so-called "Marburg monkey disease"[in German]. Dtsch Med Wochenschr 93(12):590-601, 623, 625.
51. Geisbert TW. Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, Scott DP, Kagan E, Jahrling PB, Davis KJ. 2003a. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: Evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163(6):2347-2370.
52. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, Hensley LE. 2003b. Pathogenesis of Ebola hemorrhagic fever in primate models: Evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163(6):2371-2382.
53. Geisbert TW, Jaax NK. 1998. Marburg hemorrhagic fever: Report of a case studied by immunohistochemistry and electron microscopy. Ultrastruct Pathol 22(1):3-17.
54. Gilbert J, Henske P, Singh A. 2003. Rebuilding big pharma's business model. In Vivo, the Business and Medicine Report, Windhover Information 21(10). Available online (http://www.bain.com/Images/rebuilding_big_pharma.pdf), accessed July 19, 2011.
55. Haas R, Maass G, Müller J, Oehlert W. 1968a. Experimental infection of Cercopithecus aethiops with the agent of the Frankfut-Marburg Syndrome (FMS) [in German]. Z Med Mikrobiol Immunol 154(3):210-220.
56. Haas R, Maass G, Oehlert W. 1968b. Studies on the animal-oriented pathogenicity of a Cercopithecus aethiops transmitted human pathogenic agent [in German]. Med Klin 63(35):1359-1363.
57. He Y, Hoskins JM, McLeod HL. 2011. Copy number variants in pharmacogenetic genes. Trends Mol Med 17(5):244-251.
58. Heninger S, Drysdale M, Lovchik J, Hutt J, Lipscomb MF, Koehler TM, Lyons CR. 2006. Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax. Infect Immun 74(11):6067-6074.
59. Hensley LE, Young HA, Jahrling PB, Geisbert TW. 2002. Proinflammatory response during Ebola virus infection of primate models: Possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 80(3):169-179.
60. Hornick RB, Eigelsbach HT. 1966. Aerogenic immunization of man with live tularemia vaccine. Bacteriol Rev 30(3):532-538.
61. Hugh-Jones M, Blackburn J. 2009. The ecology of Bacillus anthracis. Mol Aspects Med 30(6):356-367.
62. Hutchinson KL, Rollin PE. 2007. Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis 196(suppl 2):S357-S363.
63. Hutchinson KL, Villinger F, Miranda ME, Ksiazek TG, Peters CJ, Rollin PE. 2001. Multiplex analysis of cytokines in the blood of cynomolgus macaques naturally infected with Ebola virus (Reston serotype). J Med Virol 65(3):561-566.
64. Jaax NK, Davis KJ, Geisbert TW, Vogel P, Jaax GP, Topper M, Jahrling PB. 1996. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 120(2):140-155.
65. Johnson E, Jaax N, White J, Jahrling P. 1995. Lethal experimental infection of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol 76(4):227-236.
66. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3(8):711-715.
67. Kolesnikova LV, Ryabchikova E, Rassadkin YuN, Grazhdantseva AA. 1997. Ultrastructural stereological analysis of monkey lungs during experimental Ebola fever. B Exp Biol Med 123(2):178-181.
68. Korb G, Slenczka W. 1971. Histologic findings in livers and spleens of guinea pigs after infection by the Marburg virus. In: Martini GA, Siegert R, eds. Marburg Virus Disease. Berlin: Springer. p 123-124.
69. Kuhn JH. 2008. Filoviruses. A Compendium of 40 Years of Epidemiological, Clinical, and Laboratory Studies. Archives of Virology Suppl 20. Vienna: Springer.
70. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, Palacios G, Peters CJ, Tenorio A, Volchkov VE, Jahrling PB. 2010. Proposal for a revised taxonomy of the Family Filoviridae: Classification, names of taxa and viruses, and virus abbreviations. Arch Virol 155(12):2083-2103.
71. Leroy EM, Baize S, Debré P, Lansoud-Soukate J, Mavoungou E. 2001. Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol 124(3):453-460.
72. Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, Lansoud-Soukate J, Capron M, Debré P, McCormick JB, Georges AJ. 2000. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355(9222):2210-2215.
73. Leroy EM, Becquart P, Wauquier N, Baize S. 2011. Evidence for Ebola virus superantigen activity. J Virol 85(8):4041-4042.
74. Lub MY, Sergeyev AN, Pyankova OG, Pyankov OV, Petrishchenko VA, Kotlyarov LA. 1995. Clinical and virological characterization of the disease in guinea pigs aerogenically infected with Marburg virus [in Russian]. Vopr. Virusol. 40(3):119-121.
75. Lyons CR, Wu TH. 2007. Animal models of Francisella tularensis infection. Ann NY Acad Sci 1105:238-265.
76. Macleod M. 2011. Why animal research needs to improve. Nature 477(7366):511.
77. MacNeil A, Farnon EC, Wamala J, Okware S, Cannon DL, Reed Z, Towner JS, Tappero JW, Lutwama J, Downing R, Nichol ST, Ksiazek TG, Rollin PE. 2010. Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. Emer Infect Dis 16(12):1969-1972.
78. Makino S, Watarai M, Cheun HI, Shirahata T, Uchida I. 2002. Effect of the lower molecular capsule released from the cell surface of Bacillus Anthracis on the pathogenesis of anthrax. J Infect Dis 186(2):227-233.
79. Marsh GA, Haining J, Robinson R, Foord A, Yamada M, Barr JA, Payne J, White J, Yu M, Bingham J, Rollin PE, Nichol ST, Wang LF, Middleton D. 2011. Ebola reston virus infection of pigs: clinical significance and transmission potential. J Infect Dis 204(suppl 3):S804-S809.
80. McCrumb FR Jr, Snyder MJ, Woodward TE. 1957. Studies on human infection with Pasteurella tularensis; comparison of streptomycin and chloramphenicol in the prophylaxis of clinical disease. Trans Assoc Am Physicians 70:74-79; discussion 79-80.
81. Moayeri M, Leppla SH. 2004. The roles of anthrax toxin in pathogenesis. Curr Opin Microbiol 7(1):19-24.
82. Mogil J. 2009. Animal models of pain: Progress and challenges. Nat Rev Neurosci 10(4):283-294.
83. Mundae MK, östör AJ. 2010. The long road of biopharmaceutical drug development: From inception to marketing. QJM 103(1):3-7.
84. Murphy FA. 1978. Pathology of Ebola virus infection. In: Pattyn SR, ed. Ebola Virus Haemorrhagic Fever: Proceedings of an International Colloquium on Ebola Virus Infection and Other Haemorrhagic Fevers, December 6-8, 1977, Antwerp, Belgium. Amsterdam: Elsevier. p 43-59.
85. Murphy FA, Simpson DI, Whitfield SG, Zlotnik I, Carter GB. 1971. Marburg virus infection in monkeys: Ultrastructural studies. Lab Invest 24(4):279-291.
86. NIH [National Institutes of Health]. 2011. Emerging and Re-Emerging Infectious Diseases: Glossary. Curriculum Supplement Series-Grades 9-12. Office of Science Education, NIH. Available online (http://science.education.nih.gov/supplements/nih1/diseases/other/glossary/act1-gloss3.htm#i), accessed March 2011.
87. Okware SI, Omaswa FG, Zaramba S, Opio A, Lutwama JJ, Kamugisha J, Rwaguma EB, Kagwa P, Lamunu M. 2002. An outbreak of Ebola in Uganda. Trop Med Int Health 7(12):1068-1075.
88. Oehlert W. 1971. The morphological picture in livers, spleens, and lymph nodes of monkeys and guinea pigs after infection with the "Vervet agent". In: Martini GA, Siegert R, eds. Marburg Virus Disease. Berlin: Springer. p 144-156.
89. Peck RW. 2007. Driving earlier clinical attrition: If you want to find the needle burn down the haystack. Considerations for biomarker development. Drug Discov Today 12(7-8):289-294.
90. Pereboeva LA, Tkachev VK, Kolesnikova LV, Krendeleva L, Ryabchikova E, Smolina MP. 1993. The ultrastructural changes in guinea pig organs during the serial passage of the Ebola virus [in Russian]. Vopr Virusol 38(4):179-182.
91. Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, Macleod M, Mignini LE, Jayaram P, Khan KS. 2007. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 334(7586):197-202.
92. Phipps AJ, Premanandan C, Barnewall RE, Lairmore MD. 2004. Rabbit and nonhuman primate models of toxintargeting human anthrax vaccines. Microbiol Mol Biol Rev 68(4):617-629.
93. Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, Gibbs P, Dertzbaugh M, Friedlander AM. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19(32):4768-4773.
94. Robin Y, Brès P, Camain R. 1971. Passage of Marburg virus in guinea pigs. In: Martini GA, Siegert R, eds. Marburg Virus Disease. Berlin: Springer. p 117-122.
95. Rollin PE, Bausch DG, Sanchez A. 2007. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis 196(suppl 2):S364-S371.
96. Ross JM. 1957. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol 73(2):485-494.
97. Ruchman I, Foshay L. 1949. Immune response in mice after vaccination with Bacterium tularense. J Immunol 61(3):229-234.
98. Ryabchikova E, Baranova SG, Tkachev VK, Grazhdantseva AA. 1993. The morphological changes in Ebola infection in guinea pigs [in Russian]. Vopr Virusol 38(4):176-179.
99. Ryabchikova E, Kolesnikova L, Smolina M, Tkachev V, Pereboeva L, Baranova S, Grazhdantseva A, Rassadkin Y. 1996a. Ebola virus infection in guinea pigs: Presumable role of granulomatous inflammation in pathogenesis. Arch Virol 141(5):909-921.
100. Ryabchikova E, Strelets L, Kolesnikova L, Pyankov O, Sergeev A. 1996b. Respiratory Marburg virus infection in guinea pigs. Arch Virol 141(11):2177-2190.
101. Ryabchikova E, Kolesnikova LV, Rassadkin IuN. 1998. Microscopic study of species specific features of hemostatic impairment in Ebola virus-infected monkeys [in Russian]. Vestn Ross Akad Med Nauk 3:51-55.
102. Ryabchikova E, Kolesnikova LV, Luchko SV. 1999a. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 179(suppl. 1):S199-S202.
103. Ryabchikova E, Kolesnikova LV, Netesov SV. 1999b. Animal pathology of filoviral infections. Curr Top Microbiol Immunol 235:145-173.
104. Ryabchikova E, Smolina M, Grajdantseva A, Rassadkin J. 2004. Ebola virus infection in the guinea pig. In: Klenk HD, Feldmann H, eds. Ebola and Marburg Viruses: Molecular and Cellualar Biology. Wymondham, UK: Horizon Bioscience. p 239-254.
105. Ryabchikova E, Vorontsova LA, Skripchenko AA, Shestopalov AM, Sandakhchiev LS. 1994. Involvement of internal organs of experimental animals infected with Marburg disease virus [in Russian] Bull Exp Biol Med 117(4):430-434.
106. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD, Rollin PE. 2004. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: Cellular responses, virus load, and nitric oxide levels. J Virol 78(19):10370-10377.
107. Saslaw S, Carlisle HN. 1961. Studies with tularemia vaccines in volunteers. IV. Brucella agglutinins in vaccinated and nonvaccinated volunteers challenged with Pasteurella tularensis. Am J Med Sci 242:166-172.
108. Sawada-Hirai RS, Jiang I, Wang F, Sun SM, Nedellec R, Ruther P, Alvarez A, Millis D, Morrow PR, Kang AS. 2004. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with Anthrax Vaccine Adsorbed. J Immune Based Ther Vaccines 2(1):5.
109. Simpson DI. 1969. Vervet monkey disease. Transmission to the hamster. Br J Exp Pathol 50(4):389-392.
110. Simpson DI, Zlotnik I, Rutter DA. 1968. Vervet monkey disease. Experimental infection of guinea pigs and monkeys with the causative agent. Br J Exp Pathol 49(5):458-464.
111. Smith DH, Francis F, Simpson DIH. 1978. African haemorrhagic fever in the Southern Sudan, 1976: The clinical manifestations. In: Pattyn SR, ed. Ebola Virus Haemorrhagic Fever: Proceedings of an International Colloquium on Ebola Virus Infection and Other Haemorrhagic Fevers, December 6-8, 1977, Antwerp, Belgium. Amsterdam: Elsevier/North-Holland Biomedical Press. p 21-26.
112. Smith DH, Johnson BK, Isaacson M, Swanapoel R, Johnson KM, Killey M, Bagshawe A, Siongok T, Keruga KW. 1982. Marburg-virus disease in Kenya. Lancet 1(8276):816-820.
113. Stanford MM, McFadden G, Karupiah G, Chaudhri G. 2007. Immunopathogenesis of poxvirus infections: Forecasting the impending storm. Immunol Cell Biol 85(2):93-102.
114. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018-1028.
115. Tamimi NA, Ellis P. 2009. Drug development: From concept to marketing! Nephron Clin Pract 113(3):c125-c131.
116. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, Macleod MR. 2010. Can animal models of diseases reliably inform human studies? PLoS Med 7(3):e1000245.
117. Vasconcelos D, Barnewall R, Babin M, Hunt R, Estep J, Nielsen C, Carnes R, Carney J. 2003. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab Invest 83(8):1201-1209.
118. Vogel P, Connolly B, Abplanalp D, Geisbert TW, Kell WM, Jahrling PB, Jaax NK. 1997. Pathology of experimental Ebola-Zaire (Mayinga) virus infection transmitted to guinea-pigs by oral, conjunctival and tonsillar routes. Cell Vis 4(5):298-307.
119. Warfield KL, Alves DA, Bradfute SB, Reed DK, VanTongeren S, Kalina WV, Olinger GG, Bavari S. 2007. Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol J 4:108.
120. Warfield KL, Bradfute SB, Wells J, Lofts L, Cooper MT, Alves DA, Reed DK, VanTongeren SA, Mech CA, Bavari S. 2009. Development and characetrization of a mouse model for Marburg hemorrhagic fever. J Virol 83(13):6404-6415.
121. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. 2010. Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis 4(10):e837.
122. Welkos SL, Friedlander AM. 1988. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb Pathog 4(1):53-69.
123. WHO [World Health Organization]. 1978. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ 56(2):247-270.
124. Wu TH, Hutt JA, Garrison KA, Berliba LS, Zhou Y, Lyons CR. 2005. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis Biovar A. Infect Immun 73(5):2644-2654.
125. Wu TH, Zsemlye JL, Statom GL, Hutt JA, Schrader RM, Scrymgeour AA, Lyons CR. 2009. Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains. Vaccine 27(34):4684-4693.
126. Zaki SR, Goldsmith CS. 1999. Pathologic features of Filovirus infections in humans. Curr Top Microbiol Immunol 235:97-116.
127. Zhang F, Wu R, Qiang X, Zhou M, Wang P. 2009. Antagonism of alpha2A-adrenoceptor: A novel approach to inhibit inflammatory responses in sepsis. J Mol Med (Berl) 88(3):289-296.
128. Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med 122(11):982-992.
129. Zlotnik I. 1971. "Marburg disease". The pathology of experimentally infected hamsters. In: Martini GA, Siegert R, eds. Marburg Virus Disease. Berlin: Springer. p 129-135.
130. Zlotnik I, Simpson DI. 1969. The pathology of experimental vervet monkey disease in hamsters. Br J Exp Pathol 50(4):393-399.
131. Annas GJ. 2002. Bioterrorism, public health, and civil liberties. N Engl J Med 346(17):1337-1342
132. Annas GJ. 2005. American Bioethics: Crossing Human Rights and Health Law Boundaries. New York: Oxford University Press.
133. Annas GJ. 2010. Worst Case Bioethics: Death, Disaster, and Public Health. New York: Oxford University Press.
134. Appelbaum PS, Roth LH, Litz CW, Benson P, Winslade W. 1987. False hopes and best data: Consent to research and the therapeutic misconception. Hastings Cent Rep 17(2):20-24.
135. Beauchamp TL, Childress JF. 2001. The meaning and iustification of informed consent. In Principles of Biomedical Ethics, 5th ed. New York: Oxford University Press. p 77-98.
136. Connolly C. 2001a. Vaccine plan revives doubts on anthrax policy. Washington Post, December 24, 2001, p A01.
137. Connolly C. 2001b. Hoarding Cipro. New York Times, October 17.
138. DHHS [U.S. Department of Health and Human Services]. 2010. The Public Health Emergency Medical Countermeasures Enterprise Review: Transforming the Enterprise to Meet Long-Range National Needs. Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services. Available online (https://www.medicalcountermeasures.gov/documents/MCMReviewFinalcover-508.pdf), accessed May 2011.
139. Faden RR, Beauchamp TL. 1986. A History and Theory of Informed Consent. New York: Oxford University Press.
140. FDA [Food and Drug Administration]. 1999a. New Drug and Biological Drug Products; Evidence Needed to Demonstrate Efficacy of New Drugs for Use Against Lethal or Permanently Disabling Toxic Substances When Efficacy Studies in Humans Ethically Cannot be Conducted. Proposed Rule. Fed Regist 64(192):53960-53964.
141. FDA. 2002. New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible. Fed Regist 67(105):37988-37998.
142. FDA. 2003a. FDA Approves Pyridostigmine Bromide as Pretreatment Against Nerve Gas. FDA News: February 5, 2003. Available online (http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130342. htm), accessed July 28, 2011.
143. FDA. 2003b. Pyridostygmine Bromide Package Insert. Available online (http://www.fda.gov/downloads/drugs/emergencypreparedness/bioterrorismanddrugpreparedness/ ucm133154.pdf), accessed May 2011.
144. FDA. 2006a. FDA Approves Drug to Treat Cyanide Poisoning. FDA News: December 15, 2006. Available online (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108807.htm), accessed July 28, 2011.
145. FDA. 2006b. Cyanokit (Hydroxocobalamine): Clinical Review. Executive Summary. Available online (http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022041s000_MedR_p1.pdf), accessed May 2011.
146. FDA. 2006c. Cyanokit: Clinical Review. Available online (http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022041s000_MedR_p1.pdf), accessed May 2011.
147. FDA. 2006d. Cyanokit Pharmacology/Toxicology Review and Evaluation. Available online (http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022041_cyanokit_toc.cfm), accessed May 2011.
148. FDA. 2006e. Cyanokit Labeling, Application No. 22-041. Center for Drug Evaluation and Research, Food and Drug Administration Available online (http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022041s000_Lbl.pdf), accessed May 2011.
149. FDA. 2006f. Cyanokit Statistical Review and Evaluation. Available online (http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022041s000_StatR.pdf), accessed May 2011.
150. FDA. 2009a. Draft Guidance for Industry on Animal Models-Essential Elements to Address Efficacy Under the Animal Rule. Notice. Fed Regist 74(12):3610-3611. Available online (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm 078923.pdf), accessed May 2011.
151. FDA. 2009b. Cyanokit: Highlights of Prescribing Information. Available online (http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022041s005lbl.pdf), accessed May 2011.
152. FDA. 2009c. Briefing Package: Raxibacumab BLA 125349; Aplicant: Human Genome Sciences, Inc. Anti-Infective Drug Advisory Committee Meeting, October 27, 2009.
153. Center for Drug Evaluation and Research, Food and Drug Administration. Available online (http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM187310.pdf), accessed July 28, 2011.
154. FDA. 2009d. Vaccine Product Approval Process. Available online (http://www.fda.gov/biologicsbloodvaccines/developmentapprovalprocess/biologicslicenseapplication sblaprocess/ucm133096.htm), accessed August 2, 2011.
155. FDA. 2009e. Summary Minutes of the Anti-infective Drugs Advisory Committee Meeting, October 27, 2009. Center for Drug Evaluation and Research, Food and Drug Administration. Available online (http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM196436.pdf), accessed September 23, 2011.
156. FDA. 2010. About FDA: What We Do. Available online (http://www.fda.gov/aboutfda/whatwedo/default.htm), accessed March 2011.
157. Golomb BA. 2008. Acetylcholinesterase inhibitors and Gulf War illnesses. Proc Natl Acad Sci USA 105(11):4295-4300.
158. Grady C. 2004. Ethics of vaccine research. Nat Immunol 5(5):465-468.
159. Gronvall GK, Trent D, Borio L, Brey R, Nagao L. 2007. The FDA animal efficacy rule and biodefense. Nat. Biotechnol. 25:1084-1087.
160. HGS (Human Genome Sciences). 2011. Raxibacumab. Available online (http://www.hgsi.com/raxibacumab-2.html), accessed August 1, 2011.
161. London AJ, Kimmelman J, Emborg ME. 2010. Research ethics. Beyond access vs. protection in trials of innovative therapies. Science 328(5980):829-830.
162. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD. 2009. Raxibacumab for the treatment of inhalational anthrax. N Engl J med 361(2):135-144.
163. Miller RK. 2002. Informed consent in the military: Fighting a losing battle against the anthrax vaccine. Am J Law Med 28(2-3):325-343.
164. MVRD. org. 2011. The Military Vaccine Resource Directory. Available online (http://www.mvrd.org/index.cfm), accessed July 28, 2011.
165. Parmet WE. 2010. Pandemic vaccines -the legal landscape. N Engl J Med 362(21):1949-1952.
166. Rettig RA. 1999. Military Use of Drugs Not Yet Approved by the FDA for CW/BW Defense: Lessons from the Gulf War. Santa Monica, CA: RAND.
167. Rettig RA. 2000. Waiving Informed Consent: Military Use of Non-FDA-Approved Drugs in Combat. Research Brief RB-7534. Santa Monica, CA: RAND. Available online (http://www.rand.org/pubs/research_briefs/RB7534/index1.html), accessed July 28, 2011.
168. SteelFisher GK, Blendon RJ, Bekheit MM, Lubell K. 2010. The public's response to the 2009 H1N1 influenza pandemic. N Engl J Med 362(22):e65.
169. Anderson J, Tucker K. 2006. Development and validation of animal models. In: Swearengen JR, ed. Biodefense: Research Methodology and Animal Models. Boca Raton: CRC Press. p 41-60.
170. Chakravortty D, Hensel M. 2003. Inducible nitric oxide synthase and control of intracellular bacterial pathogens. Microbes Infect 5(7):621-627.
171. DHHS [U.S. Department of Health and Human Services]. 2010. The Public Health Emergency Medical Countermeasures Enterprise Review: Transforming the Enterprise to Meet Long-Range National Needs. Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services. Available online (https://www.medicalcountermeasures.gov/documents/MCMReviewFinalcover-508.pdf), accessed May 2011.
172. FDA [Food and Drug Administration]. 1995. FDA Guidance for Industry. Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products. Center for Drug Evaluation, Center for Biologics Evaluation and Research, Food and Drug Administration. Available online (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm 071597.pdf), accessed March 2011.
173. FDA. 2001. FDA Guidance for Industry. IND Meetings for Human Drugs and Biologics: Chemistry, Manufacturing, and Controls Information. Available online (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UC M070568.pdf), accessed March 2011).
174. FDA. 2002. New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible. Fed Regist 67(105):37988-37998.
175. FDA. 2009a. Draft Guidance for Industry on Animal Models-Esential Elements to Address Efficacy Under the Animal Rule. Notice. Fed. Regist 74(12)3610-3611. Available online (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm 078923.pdf), accessed May 2011.
176. FDA. 2009b. Summary Minutes of the Anti-infective Drugs Advisory Committee Meeting, October 27, 2009. Center for Drug Evaluation and Research, Food and Drug Administration. Available online (http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM196436.pdf), accessed September 23, 2011.
177. Goossens PL. 2009. Animal models of anthrax: The Quest for the Holy Grail. Mol Aspects Med 30(6):467-480.
178. Hartung T. 2007. Food for thought on validation. ALTEX 24(2):67-73
179. Hoffmann S, Edler L, Gardner I, Gribaldo L, Hartung T, Klein C, Liebsch M, Sauerland S, Schechtman L, Stammati A, Nikolaidis E. 2008. Points of reference in validation: The report and recommendations of ECVAM Workshop 66. Altern Lab Anim 36(3):343-352.
180. ICH [International Conference on Harminization of technical Requirements for Registration of Pharmaceuticals for Human Use]. 2005. ICH Harmonized Tripartite Guideline. Validation of Analytical Procedures:Text and Methodology Q2(R1). Available online (http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q 2_R1__Guideline.pdf), assessed September 2011.
181. Jahrling PB, Hensley LE, Martinez MJ, LeDuc JW, Rubins KH, Relman DA, Huggins JW. 2004. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci USA 101(42):15196-15200.
182. Loving CL, Khurana T, Osorio M, Lee GM, Kelly VK, Stibitz S, Merkel TJ. 2009. Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model. Infect Immun. 77(1):255-265.
183. McFadden G. 2005. Poxvirus tropism. Nat Rev Microbiol 3(3):201-213.
184. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD. 2009. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 361(2):135-144.
185. Walker RL, King NMP. 2011. Biodefense research and the U.S. regulatory structure. Whither nonhuman primate moral standing? Kennedy Inst Ethics J 2193):277-310.
186. Warfield KL, Jaax NK, Deal EM, Swenson DL, Larsen T, Bavari S. 2006. Viral hemorrhagic fevers. In: Swearengen JR, ed. Biodefense: Research Methodology and Animal Models. Boca Raton: CRC Press. p 227-257.
187. Yang CS, Yuk JM, Jo EK. 2009. The role of nitric oxide in mycobacterial infections. Immune Netw 9(2):46-52. Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V, Andersen KE, Angers-Loustau A, Aptula A, Bal-Price A., Benfenati E, Bernauer U, Bessems Jos, Bois FY, Boobis A, Brandon E, Bremer S, Broschard T, Casati S, Coecke S, Corvi R, Cronin M, Daston G, Dekant W, Felter S, Grignard E, Gundert-Remy U, Heinonen T, Kimber I, Kleinjans J, Komulainen H, Kreiling R, Kreysa J, Batista Leite S, Loizou G, Maxwell G, Mazzatorta P, Munn S, Pfuhler S, Phrakonkham P, Piersma A, Poth A, Prieto P, Repetto G, Rogiers V, Schoeters G, Schwarz M, Serafimova R, Tahti H, Testai E, van Delft J, van Loveren H, Vinken M, Worth A, Zaldivar JM. 2011. Alternative (non-animal) methods for cosmetics testing: current status and future prospects -2010. Arch Toxicol 85(5):367-485.
188. Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V, Andersen KE, Angers-Loustau A, Aptula A, Bal-Price A., Benfenati E, Bernauer U, Bessems Jos, Bois FY, Boobis A, Brandon E, Bremer S, Broschard T, Casati S, Coecke S, Corvi R, Cronin M, Daston G, Dekant W, Felter S, Grignard E, Gundert-Remy U, Heinonen T, Kimber I, Kleinjans J, Komulainen H, Kreiling R, Kreysa J, Batista Leite S, Loizou G, Maxwell G, Mazzatorta P, Munn S, Pfuhler S, Phrakonkham P, Piersma A, Poth A, Prieto P, Repetto G, Rogiers V, Schoeters G, Schwarz M, Serafimova R, Tahti H, Testai E, van Delft J, van Loveren H, Vinken M, Worth A, Zaldivar JM. 2011. Alternative (non-animal) methods for cosmetics testing: current status and future prospects -2010. Arch Toxicol 85(5):367-485
189. Alkhalil A, Hammamieh R, Hardick J, Ichou MA, Jett M, Ibrahim S. 2010. Gene expression profiling of monkeypox virus-infected cells reveals novel interfaces for host-virus interactions. Virol J 7:173.
190. Baer-DubowskaW, Majchrzak-Celinska A, Cichocki M. 2011. Pharmacoepigenetics: A new approach to predicting individual drug responses and targeting new drugs. Pharmacol Rep 63(2):293-304.
191. Bateson P. 2011. Review of Research Using Non-Human Primates. Available online (http://www.mrc.ac.uk/Utilities/Documentrecord/index.htm?d=MRC008083), accessed September 2011.
192. Churchill GA, Airey DC, Allayee H, Angel JM, Attie AD, Beatty J, Beavis WD, Belknap JK, Bennett B, Berrettini W, Bleich A, Bogue M, Broman KW, Buck KJ, Buckler E, Burmeister M, Chesler EJ, Cheverud JM, Clapcote S, Cook MN, Cox RD, Crabbe JC, Crusio WE, Darvasi A, Deschepper CF, Doerge RW, Farber CR, Forejt J, Gaile D, Garlow SJ, Geiger H, Gershenfeld H, Gordon T, Gu J, Gu W, de Haan G, Hayes NL, Heller C, Himmelbauer H, Hitzemann R, Hunter K, Hsu HC, Iraqi FA, Ivandic B, Jacob HJ, Jansen RC, Jepsen KJ, Johnson DK, Johnson TE, Kempermann G, Kendziorski C, Kotb M, Kooy RF, Liamas B, Lammert F, Lassalle JM, Lowenstein PR, Lu L, Lusis A, Manly KF, Marcucio R, Matthews D, Medrano JF, Miller DR, Mittleman G, Mock BA, Mogil JS, Montagutelli X, Morahan G, Morris DG, Mott R, Nadeau JH, Nagase H, Nowakowski RS, O'Hara BF, Osadchuk AV, Page GP, Paigen B, Paigen K, Palmer AA, Pan HJ, Peltonen-Palotie L, Peirce J, Pomp D, Pravenec M, Prows DR, Qi Z, Reeves RH, Roder J, Rosen GD, Schadt EE, Schalkwyk LC, Seltzer Z, Shimomura K, Shou S, Sillanpää MJ, Siracusa LD, Snoeck HW, Spearow JL, Svenson K, Tarantino LM, Threadgill D, Toth LA, Valdar W, de Villena FP, Warden C, Whatley S, Williams RW, Wiltshire T, Yi N, Zhang D, Zhang M, Zou F; Complex Trait Consortium. 2004. The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet 36(11):1133-1137.
193. Collins FS, Gray GM, Bucher JR. 2008. Toxicology: Transforming environmental health protection. Science 319(5865):906-907.
194. Cookson W, Liang L, Abecasis G, Moffatt M, Lathrop M. 2009. Mapping complex disease traits with global gene expression. Nat Rev Genet 10(3):184-194.
195. Das R, Hammamieh R, Neill R, Ludwig GV, Eker S, Lincoln P, Ramamoorthy P, Dhokalia A, Mani S, Mendis C, Cummings C, Kearney B, Royaee A, Huang XZ, Paranavitana C, Smith L, Peel S, Kanesa-Thasan N, Hoover D, Lindler LE, Yang D, Henchal E, Jett M. 2008. Early indicators of exposure to biological threat agents using host gene profiles in peripheral blood mononuclear cells. BMC Infect Dis 8:104.
196. DHHS [U.S. Department of Health and Human Services]. 2010. The Public Health Emergency Medical Countermeasures Enterprise Review: Transforming the Enterprise to Meet Long-Range National Needs. Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services. Available online (https://www.medicalcountermeasures.gov/documents/MCMReviewFinalcover-508.pdf), accessed May 2011.
197. Durant C, Tayem H, Yalcin B, Cleak J, Goodstadt L, Pardo-Manuel de Villena P, Mott R, Iraqi FA. 2011. Collaborative Cross mice and the power to map host susceptibility to Aspergillus fumigatus infection. Genome Res 21(8):1239-1248.
198. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Brakenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmit J. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333(6044):843-850.
199. FDA [Food and Drug Administration]. 2002. New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible. Fed Regist 67(105):37988-37998.
200. FDA. 2009a. Guidance for Industry. Animal Models -Essential Elements to Address Efficacy Under the Animal Rule. Available online (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm 078923.pdf), accessed May 2011.
201. FDA. 2009b. Summary Minutes of the Anti-infective Drugs Advisory Committee Meeting, October 27, 2009. Center for Drug Evaluation and Research, Food and Drug Administration. Available online (http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM196436.pdf), accessed September 23, 2011.
202. FDA. 2010. NIH and FDA Announce Collaborative Initiative to Fast-Track Innovations to the Public. FDA-NIH News Release: February 24, 2010. Available online (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm201706.htm), accessed June 2011.
203. Fernandez JG, Khademhosseini A. 2010. Micro-masonry: Construction of 3D structures by microscale selfassembly. Adv Mater 22(23):2538-2541.
204. Fleishman SJ, Whitehead TA, Ekiert DC, Dreyfus C, Corn JE, Strauch EM, Wilson IA, Baker D. 2011. Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 332(6031):816-821.
205. Gaucher D., Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, Moser JM, Mehta RS, Drake DR, III, Castro E, Akondy R, Rinfret A, Yassine-Diab B, Said EA, Chouikh Y, Cameron MJ, Clum R, Kelvin D, Somogyi R, Greller LD, Balderas RS, Wilkinson P, Pantaleo G, Tartaglia J, Haddad EK, Sékaly RP. 2008. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205(13):3119-3131.
206. Hamburg MA. 2011. Advancing regulatory science. Science 331(6020):987.
207. Hamburg MA, Collins FS. 2010. The path to personalized medicine. N Engl J Med 363:301-304. [Erratum, N Engl J Med 2010; 363:1092.]
208. Hartung T, Blaauboer BJ, Bosgra S, Carney E, Coenen J, Conolly RB, Corsini E, Green S, Faustman EM, Gaspari A, Hayashi M, Wallace Hayes A, Hengstler JG, Knudsen LE, Knudsen TB, McKim JM, Pfaller W and Roggen EL. 2011. An expert consortium review of the EC-commissioned report "Alternative (Non-Animal) Methods for Cosmetics Testing: Current Status and Future Prospects -2010". ALTEX 28(3):183-209.
209. Higbee RG, Byers AM, Dhir V, Drake D, Fahlenkamp HG, Gangur J, Kachurin A, Kachurina O, Leistritz D, Ma Y, Mehta R, Mishkin E, Moser J, Mosquera L, Nguyen M, Parkhill R, Pawar S, Poisson L, Sanchez-Schmitz G, Schanen B, Singh I, Song H, Tapia T, Warren W, Wittman V. 2009. An immunologic model for rapid vaccine assessment -a clinical trial in a test tube. Altern Lab Anim 37(suppl 1):19-27.
210. Hooper JW, Thompson E, Wilhelmsen C, Zimmerman M, Ichou MA, Steffen SE, Schmaljohn CS, Schmaljohn AL, Jahrling PB. 2004. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol 78(9):4433-4443.
211. Ingber DE, Mow VC, Butler D, Niklason L, Huard J, Mao J, Yannas I, Kaplan D, Vunjak-Novakovic G. 2006. Tissue engineering and developmental biology: Going biomimetic. Tissue Eng 12(12):3265-3268.
212. Jahrling PB, Hensley LE, Martinez MJ, LeDuc JW, Rubins KH, Relman DA, Huggins JW. 2004. Exploring the potential of variola virus infection of cynomologus macaques as a model for human smallpox. Proc Natl Acad Sci USA 101(42):15196-15200.
213. Judson RS, Houck KA, Kavlock RJ, Knudsen TB, Martin MT, Mortensen HM, Reif DM, Rotroff DM, Shah I, Richard AM, Dix DJ. 2010. In vitro screening of environmental chemicals for targeted testing prioritization: The ToxCast project. Environ Health Perspect 118(4):485-492.
214. Kang SM, Song JM, Compans RW. 2011. Novel vaccines against influenza viruses. Virus Res. Oct 1. [Epub ahead of print] doi:10.1016/j.virusres.2011.09.037.
215. Khodakevich L, Jezek Z, Kinzanzka K. 1986. Isolation of monkeypox virus from wild squirrel infected in nature. Lancet 1(8472):98-99.
216. Khodakevich L, Szczeniowski M, Manbu-ma-Disu, Jezek Z, Marennikova S, Nakano J, Messinger D. 1987a. The role of squirrels in sustaining monkeypox virus transmission. Trop Geogr Med 39(2):115-122.
217. Khodakevich L, Szczeniowski M, Manbu-ma-Disu, Jezek Z, Marennikova S, Nakano J, Meier F. 1987b. Monkeypox virus in relation to the ecological features surrounding human settlements in Bumba zone, Zaire. Trop Geogr Med 39(1):56-63.
218. Kotb M. 2010. Septomics: Application of systems approaches to sepsis -potential for personalized management of septic patients. Curr Pharmacogenomics Person Med 8(2):97-107.
219. Kotb M, Fathey N, Aziz R, Rowe S, Williams RW, Lu L. 2008. Unbiased forward genetics and systems biology approaches to understanding how gene-environment interactions work to predict susceptibility and outcomes of infections. Novartis Found Symp 293:156-65; discussion 165-167, 181-183.
220. Mammoto T, Ingber DE. 2010. Mechanical control of tissue and organ development. Development 137(9):1407-1420.
221. Martignioni M, Groothuis GM, de Kanter R. 2006. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2(6):875-894.
222. McFadden G. 2005. Poxvirus tropism. Nat Rev Microbiol 3(3): 201-213.
223. Miller FG, Silverman HJ. 2004. The ethical relevance of the standard of care in the design of clinical trials. Am J Respir Crit Care Med 169(5):562-564.
224. Miller M, Schneider J, Sathyanarayana BK, Toth MV, Marshall GR, Clawson L, Selk L, Kent SB, Wlodawer A. 1989. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science 246(4934):1149-1152.
225. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. 1979. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Available online (http://ohsr.od.nih.gov/guidelines/belmont.html), accessed May 2011.
226. Nature Genetics. 2011. No second thoughts about data access. 43(5):389.
227. Nemzek JA, Xiao H-Y, Minard AE, Bolgos GL, Remick DG. 2004. Humane endpoints in shock research. Shock 21(1):17-25.
228. NRC [National Research Council]. 2007. Toxicity Testing in the 21st Century: A Vision and A Strategy. Washington, DC: National Academies Press.
229. NRC. 2008. Recognition and Alleviation of Distress in Laboratory Animals. Washington, DC: National Academies Press.
230. NRC. 2009. Recognition and Alleviation of Pain in Laboratory Animals. Washington, DC: National Academies Press.
231. NRC. 2011. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academies Press.
232. Olfert ED, Godson DL. 2000. Humane endpoints for infectious disease animal models. ILAR J 41(2):99-104.
233. Ploss A, Khetani SR, Jones CT, Syder AJ, Trehan K, Gaysinskaya VA, Mu K, Ritola K, Rice CM, Bhatia SN. 2010. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci USA 107(7):3141-3145.
234. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, Blumberg S, Thomassen HA, Pike BL, Fair JN, Wolfe ND, Shongo RL, Graham BS, Formenty P, Okitokolonda E, Hensley LE, Meyer H, Wright LL, Muyembe J-J. 2010. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Nat Acad Sci USA 107(37):16262-16267.
235. Russell WMS, Burch RL. 1959. The Principles of Humane Experimental Technique. London: Methuen. Available online (http://altweb.jhsph.edu/pubs/books/humane_exp/het-toc), accessed March 2011.
236. Sasaki E, Suemizu H, Shimada A, Hanazawa K, Oiwa R, Kamioka M, Tomioka I, Sotomaru Y, Hirakawa R, Eto T, Shiozawa S, Maeda T, Ito M, Ito R, Kito C, Yagihashi C, Kawai K, Miyoshi H, Tanioka Y, Tamaoki N, Habu S, Okano H, Nomura T. 2009. Generation of transgenic non-human primates with germline transmission. Nature. 459 (7246):523-527.
237. Schanen BC, De Groot AS, Moise L, Ardito M, McClaine E, Martin W, Wittman V, Warren WL, Drake DR, III. 2011. Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus. Vaccine 29(17):3299-3309.
238. Schanen BC, Drake DR, III. 2008. A novel approach for the generation of human dendritic cells from blood monocytes in the absence of exogenous factors. J Immunol Methods 335(1):53-64.
239. Smith GL. 1999. Vaccinia virus immune evasion. Immunol Lett 65(1-2):55-62.
240. Talele TT, Khedkar SA, Rigby AC. 2010. Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. Curr Top Med Chem 10(1):127-141.
241. Thomson G. 1995. Analysis of complex human genetic traits: An ordered-notation method and new tests for mode of inheritance. Am J Hum Genet 57(2):474-486.
242. Toussaint NC, Mama Y, Kohlbacher O, Louzoun Y. 2011. Universal peptide vaccines -Optimal peptide vaccine design based on viral sequence conservation. Vaccine 29(47):8745-8753.
243. Villar J Maca-Meyer N, Pérez-Méndez I, Flores C. 2004. Bench-to-bedside review: Understanding genetic predisposition to sepsis. Crit Care 8(3):180-189.
244. Voit EO, Qi Z, Miller GW. 2008. Steps of modeling complex biological systems. Pharmacopsychiatry 41(suppl 1):S78-S84.
245. Walker RL, King NMP. 2011. Biodefense research and the U.S. regulatory structure. Whither nonhuman primate moral standing? Kennedy Inst Ethics J 2193):277-310.
246. Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, Wilson IA, García-Sastre A, Moran TM, Palese P. 2010. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci 107(44):18979-18984.
247. WHO [World Health Organization]. 2011. Smallpox: Fact sheet. Available online (http://www.who.int/mediacentre/factsheets/smallpox/en/), accessed March 2011.
248. Williams RW. 2006. Expression genetics and the phenotype revolution. Mamm Genome 17(6):496-502.
249. Williams RW Gu J, Lu L. 2001. The genetic structure of recombinant inbred mice: High-resolution consensus maps for complex trait analysis. Genome Biol 2(11):46.
250. Wolfe ND, Escalante AA, Karesh WB, Kilbourn A, Spielman A, Lai AA. 1998. Wild primate populations in emerging infectious disease research: The missing link? Emerg Infect Dis 4 (2):149-158.
251. Wolfer DP, Litvin O, Morf S, Nitsch RM, Lipp H-P, Würbel H. 2004. Laboratory animal welfare: Cage enrichment and mouse behavior. Nature 432(7019):821-822.